Advances in pediatric pulmonary arterial hypertension
- 1 March 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Cardiology
- Vol. 27 (2), 70-81
- https://doi.org/10.1097/hco.0b013e32835018cd
Abstract
Purpose of review Pulmonary arterial hypertension (PAH) is an important cause of morbidity and mortality in children. Approved medications for the treatment of adult PAH have been used to treat children, but evidence-based treatment algorithms for children are lacking. Recent findings Pediatric PAH registries have begun to define the incidence and prevalence of idiopathic PAH and PAH associated with congenital heart disease. A pediatric-specific classification of pulmonary hypertensive vascular disease has been proposed. Furthermore, the first randomized placebo-controlled trial of type-5 phosphodiesterase therapy in treatment-naïve children with PAH has been completed and reported. This trial highlights the importance of the difficulties of performing clinical trials in children with targeted PAH therapy as well as the importance of long-term follow-up of adverse events. Summary Classification, clinical trials, and therapy for children with PAH must take into account the unique aspects of PAH in children.Keywords
This publication has 75 references indexed in Scilit:
- Circulating fibrocytes are increased in children and young adults with pulmonary hypertensionEuropean Respiratory Journal, 2011
- Recent progress in understanding pediatric pulmonary hypertensionCurrent Opinion in Pediatrics, 2011
- Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular diseaseCardiology in the Young, 2010
- Medical Therapy for Pediatric Pulmonary Arterial HypertensionThe Journal of Pediatrics, 2010
- Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary HypertensionThe Journal of Pediatrics, 2009
- Tadalafil for the treatment of pulmonary arterial hypertensionExpert Opinion on Pharmacotherapy, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance ProgramPediatric Research, 2008
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2005
- Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crisesThe Journal of Thoracic and Cardiovascular Surgery, 2002